Adienne Pharma and Biotech

Focus: Adienne Pharma and Biotech is an Italian-headquartered specialist in biologics and biosimilars with a focused commercial portfolio spanning infectious diseases, gastroenterology, and oncology. The company operates as a mid-cap specialty pharma with heavy dependence on a single marketed asset.

Infectious Diseases Gastroenterology Oncology Unknown

Profile data last refreshed 1h ago · AI intelligence enriched 3w ago

Open Jobs

About Adienne Pharma and Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Adienne Pharma and Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

RUBRACA

Oncology

$43M

Peak9.0yr

Drives 100% of company revenue; NDA-approved PARP inhibitor with patent protection through 2035 providing 10+ years of exclusivity runway.

Help build intelligence for Adienne Pharma and Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio includes RUBRACA (rucaparib), a peak-lifecycle oncology asset generating $43M in Part D spending with LOE protection until 2035, offering stable commercial execution opportunity.
Biologics and biosimilars specialization provides exposure to high-value therapeutic modalities in growing therapeutic areas including oncology and infectious diseases.
European base offers career path in a growing specialty pharma market with regulatory expertise in EMA submissions alongside FDA experience.

Watch Out For

100% revenue concentration in a single drug (RUBRACA) creates extreme commercial risk; loss of market position, generic competition acceleration, or clinical setback would materially impact job security.
Zero active clinical trials and empty pipeline signal minimal R&D momentum and limited career development in drug discovery/development roles; company appears to be a commercial and distribution entity rather than a research organization.
Active shortage in PEGASYS (peginterferon alfa-2a) and approaching LOE for secondary assets suggest operational/supply-chain constraints and declining revenue diversification over the medium term.

Interview Prep Quick Facts

Portfolio: 4 approved products

Top TAs: Oncology, Gastroenterology, Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Peak3 (75%)

LOE Approaching1 (25%)

4 total products

Therapeutic Area Focus

4 marketed

1 marketed

1 marketed

1 marketed

Marketed

Pipeline

Risk Signals

1 active drug shortage

Active supply-chain shortage in PEGASYS (peginterferon alfa-2a) signals operational/manufacturing risk; no layoff history provided, but extreme single-asset revenue concentration and zero pipeline present restructuring risk if RUBRACA faces competitive or regulatory pressure.

Adienne Pharma and Biotech

About Adienne Pharma and Biotech

Why Work Here

Key Products

Watch Out For

Products & Portfolio (3)

Key Products by Revenue

Other Products (1)

Open Jobs (0)

Risk Signals